|
MAXITROL
The ophthalmic preparation of MAXITROL combines two antibiotics offering broad spectrum antibacterial activity with the anti-inflammatory activity of a new corticosteroid: dexamethasone, for combating certain microbial infections of the anterior segment of the eye. The suspension is formulated in an isotonic menstrum containing hydroxypropyl methylcellulose for maximum effectiveness and comfort.
COMPOSITION
Each ml.: neomycin (I.N.N.) sulfate 3,500 I.U., polymyxin B (I.N.N.) sulfate 6,000 I.U., dexamethasone (I.N.N.) 1 mg., benzalkonium chloride (preservative) 0,04 mg., sodium chloride, polysorbate 20, hydroxypropyl methylcellulose, hydrochloric acid and / or sodium hydroxide and purified water q.s.
INDICATIONS
MAXITROL is indicated for the treament of infectious ocular inflammations produced by organisms which are sensitive to the antibiotics Neomycin Sulphate and Polymyxin B.
Acute or chronic non-purulent conjunctivitis, blepharoconjunctivitis and keratoconjunctivitis.
Non-specific superficial keratitis, deep keratitis and acne rosacae keratitis.
Iridocyclitis.
Mild acute iritis.
Recurrent marginal ulceration.
Corneal ulcer.
Non-purulent blepharitis.
Scleritis, episcleritis and scleroconjunctivitis.
Postoperatively to aid in the prevention of ophthalmic cases of infections.
CONTRAINDICATIONS
MAXITROL is contraindicated in those persons who have shown hypersensitivity to any of its components, in tubercular, fungal and viral lesions of the eye (dendritic keratitis, herpes simplex), vaccinia, varicella, acute purulent conjunctivitis and acute purulent blepharitis. It is contraindicated in patients with a history or family history of glaucoma.
PRECAUTIONS
Prolonged use of topical steroids may result in elevation of intraocular pressure (IOP) in some patients. Intraocular pressure should be routinely monitored.
In those diseases causing thinning of the cornea, perforations have been known to occur with the use of topical steroids.
WARNINGS
Sportspersons should be aware that this medication contains a component which may give a positive test result in a doping control.
Warnings about excipients:
This medication contains the excipient benzalkonium chloride, which may discolour soft contact lenses. If you use contact lenses, you should take them out before applying this product and they should not be worn until at least 10 to 15 minutes following the instillation of the drops.
SIDE EFFECTS
Prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Some people may experience hypersensitivity to one or more components of this medication. If hypersensitivity develops with this product, discontinue use.
INCOMPATIBILITIES
None reported.
OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
If MAXITROL is used as recommended overdosage is unlikely to occur. In the case of overdose or accidental ingestion immediately consult your local poison control centre and indicate the medication and the amount taken.
POSOLOGY
One or two drops topically in the conjunctival sac four or six times daily. Dosage may be reduced after three or four days if satisfactory improvement has been obtained.
INSTRUCTIONS FOR THE CORRECT ADMINISTRATION OF THE PRODUCT
Shake the bottle well before use.
SPECIAL PRECAUTIONS FOR STORAGE
Do not store above 25°C. Do not refrigerate.
Do not allow dropper tip to touch any surface as this may contaminate the contents.
This medicine must be discarded one month after first opening.
PRESENTATION
MAXITROL is supplied in a 5 ml. eye-dropper.
ALL MEDICATIONS MUST BE KEPT OUT OF THE REACH AND SIGHT OF CHILDREN
/ BUY MAXITROL /
|
|
CONTACT INFORMATION
